The life sciences industry suffers from a lack of gender diversity. Women entrepreneurs are being overlooked for raising seed-stage money when launching a new company. According to the Association for Women in Science, less than 15% of angel funding and only 2% of venture capital is directed to companies started or led by women.
To address this critical need, AFCR worked with our strategic partners, the National Foundation for Cancer Research and AIM-HI Accelerator Fund (AIM-HI) to launch the AIM-HI Women’s Venture Competition, a first-of-its-kind initiative designed to highlight, energize and fund promising cancer treatment technology companies led by female scientist-entrepreneurs.
The Competition is to support women-led life-saving start-ups through venture philanthropy partnerships and providing these companies with valuable access to key opinion leaders. The combination of funding, insightful feedback from life sciences industry figures, increased visibility and credibility, and opportunity to tap into so extensive a global network is highly unique and impactful.
2021 Women’s Venture Competition
The Asian Fund for Cancer Research together with its strategic partner, the AIM-HI Accelerator Fund, is pleased to present the 2021 Women’s Venture Competition. Subject to due diligence and negotiation, the winning company will receive US$1 million in investment funding. Outside of the investment, “Rising Star” and “Most Innovative Technology” prizes will be awarded to chosen contestants. Learn more.
2020 Women’s Venture Competition
A fabulous evening on September 24, 2020, celebrating our 8 amazing semi-finalists and their companies at the Awards Ceremony for the inaugural Women’s Venture Competition. The Awards Ceremony started with revealing the People’s Choice Award for Best Pitch winner, Dr. María José Alonso of Libera Bio, and moved to announcing our top two Finalists… Learn more.
2020 Women’s Venture Competition Winner
Privo Technologies has received investment of $900,000 – $300,000 from AIM-HI and matching investment from two supporters of the Competition! Read the press release.
Based in Peabody, Massachusetts, the company has developed a nano-engineered platform for redesigning the mechanism of action of potent cancer medicines. For more information, visit https://www.privotechnologies.com.